Non-melanoma skin cancers and human papillomavirus;Cancers cutanés non mélaniques et papillomavirus humains

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 12 I, 2003, Pages 1131-1138

  Aubin, F ^a   Humbey, O ^a   Guerrini J S ^a   Mougin, C ^a   Laurent, R ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ONCOPROTEIN; PROLINE; PROTEIN E6; PROTEIN E7; PROTEIN P53; VIRUS PROTEIN;

BENIGN TUMOR; CANCER RISK; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EPIDERMODYSPLASIA VERRUCIFORMIS; GENETIC PREDISPOSITION; HUMAN; NON MELANOMA SKIN CANCER; RADIATION EXPOSURE; REVIEW; SKIN CARCINOGENESIS; SUN EXPOSURE; ULTRAVIOLET RADIATION; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS LOAD; WART VIRUS;

APOPTOSIS; CELL DIVISION; GENES, P53; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SKIN NEOPLASMS;

EID: 0348225382     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Soufir N, Moles JP, Vilmer C, Moch C, Verola O, Rivet J et al. P16 UV mutations in human skin epithelial tumors. Oncogene 1999;18:5477-81.
2. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
3. Mougin C, Bernard B, Lab M. Biologie des infections à papillomavirus. I. Charactéristiques générales. Ann Biol Clin (Paris) 1997;55:555-63.
4. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002;15:101-14.
5. de Villiers EM. Human papillomavirus infections in skin cancers. Biomed Pharmacother 1998;52:26-33.
6. Boxman IL, Mulder LH, Russell A, Bouwes Bavinck JN, Green A, Ter Schegget J. Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br J Dermatol 1999;141:246-9.
7. Pfister H, ter Schegget J. Role of HPV in cutaneous premalignant and malignant tumors. Clin Dermatol 1997;15:335-47.
8. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-97.
9. Meyer T, Arndt R, Christophers E, Nindl I, Stockfleth E. Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev 2001;25:533-47.
10. Cairey-Remonnay S, Humbey O, Mougin C, Algros MP, Mauny F, Kanitakis J et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol 2002;118:1026-31.
11. Derancourt C, Mougin C, Chopard Lallier M, Coumes-Marquet S, Drobacheff C, Laurent R. Papillomavirus humains oncogènes révé lés par technique d'hybridation in situ dans la maladie de Bowen extra-génitale. Ann Dermatol Venereol 2001;128:715-8.
12. Storey A. Papillomaviruses: death-defying acts in skin cancer. Trends Mol Med 2002;8:417-21.
13. Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579-81.
14. Majewski S, Jablonska S. Do epidermodysplasia verruciformis human papillomaviruses contribute to malignant and benign epidermal proliferations? Arch Dermatol 2002;138:649-54.
15. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996;61:715-21.
16. Euvrard S, Chardonnet Y, Pouteil-Noble C, Kanitakis J, Chignol MC, Thivolet J et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993;72:2198-206.
17. Boxman IL, Berkhout RJ, Mulder LH, Wolkers MC, Bouwes Bavinck JN, Vermeer BJ et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997;108:712-5.
18. de Jong-Tieben LM, Berkhout RJ, ter Schegget J, Vermeer BJ, de Fijter JW, Bruijn JA et al. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 2000;69:44-9.
19. Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S. Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 1998;110:311-7.
20. Mahe E, Descamps V. PUVA therapy and human papillomavirus type 5 detection in psoriasis. J Invest Dermatol 1998;111:912-3.
21. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999;135:1104-10.
22. Aubin F. Photoimmunologie. Encycl. Méd. Chir. (Elsevier, Paris), Dermatologie 2002;98-780-A-10, 7 p.
23. Weissenborn SJ, Hopfl R, Weber F, Smola H, Pfister HJ, Fuchs PG. High prevalence of a variety epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol 1999;113:122-6.
24. Bayle-Lebey P, Labadie F, Basset-Seguin N, Bazex J. Carcinomes cutanés et papillomavirus 5. Révélation lors d'une photochimiothérapie UVA prolongée. Ann Dermatol Venereol 1994;121:496-8.
25. Harwood CA, Spink PJ, Surentheran T et al. Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. J Invest Dermatol 1998;111:123-7.
26. Zumtobel U, Schwarze HP, Favre M, Taieb A, Delaunay M. Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients. Dermatology 2001;202:127-30.
27. Aubin F, Humbey O, Guerrini JS, Laurent R, Mougin C. Ultraviolet et papillomavirus humains. In Aubin F, Prétet JL, Mougin C. Les papillomavirus humains: Biologie et Pathogie Tumorale. Editions Tec et Doc-Lavoisier, Paris, 2003 (in press).
28. Zhang P, Nouri M, Brandsma JL, Iftner T, Steinberg BM. Induction of E6/ E7 expression in cottontail rabbit papillomavirus latency following UV activation. Virology 1999;263:388-94.
29. Wikonkal NM, Brash DE. Ultraviolet radiation induced signature mutations in photocarcinogenesis. J Investig Dermatol Symp Proc 1999;4:6-10.
30. Steger G, Pfister H. In vitro expressed HPV 8 E6 protein does not bind P53. Arch Virol 1992;125:355-60.
31. Yamashita T, Segawa K, Fujinaga Y, Nishikawa T, Fujinaga K. Biological and biochemical activity of E7 genes of the cutaneous human papillomavirus type 5 and 8. Oncogene 1993;8:2433-41.
32. McGregor JM, McKee PH, Khorshid M, Proby CM. P53 expression and human papillomavirus infection in transplant recipients and in patients with epidermodysplasia verruciformis. Br J Dermatol 1996;134:374.
33. Gibson GE, O'Grady A, Kay EW, Leader M, Murphy GM. P53 tumor suppressor gene protein expression in premalignant and malignant skin lesions of kidney transplant recipients. J Am Acad Dermatol 1997;36:924-31.
34. McGregor JM, Berkhout RJ, Rozycka M, ter Schegget J, Bouwes Bavinck JN, Brooks L et al. P53 mutations implicate sunlight in posttransplant skin cancer irrespective of human papillomavirus status. Oncogene 1997;15:1737-40.
35. Padlewska K, Ramoz N, Cassonnet P, Riou G, Barrois M, Majewski S et al. Mutation and abnormal expression of the P53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. J Invest Dermatol 2001;117:935-42.
36. Euvrard S, Kanitakis J, Claudy, A. Tumeurs cutanées chez les greffés d'organe. Presse Med 2002;31:1895-903.
37. Purdie KJ, Pennington J, Proby CM, Khalaf S, de Villiers EM, Leigh IM et al. The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus P53 binding sequence. Embo J 1999;18:5359-69.
38. Ruhland A, de Villiers EM. Opposite regulation of the HPV 20-URR and HPV 27-URR promoters by ultraviolet irradiation and cytokines. Int J Cancer 2001;91:828-34.
39. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F et al. Role of a P53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
40. McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'nions J et al. Relationship between P53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002;119:84-90.
41. Ramsay HM, Harden PN, Reece S, Smith AG, Jones PW, Strange RC et al. Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis. J Invest Dermatol 2001;117:251-5.
42. Loignon M, Drobetsky EA. The initiation of UV-induced G(1) arrest in human cells is independent of the P53/P21/pRb pathway but can be attenuated through expression of the HPV E7 oncoprotein. Carcinogenesis 2002;23:35-45.
43. Gabrielli BG, Sarcevic B, Sinnamon J, Walker G, Castellano M, Wang XQ et al. A cyclin D-Cdk4 activity required for G2 phase cell cycle progression is inhibited in ultraviolet radiation-induced G2 phase delay. J Biol Chem 1999;274:13961-9.
44. Chazal M, Marionnet C, Michel L, Mollier K, Dazard JE, Della Valle V et al. P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation. Oncogene 2002;21:2652-61.
45. Giarre M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J Virol 2001;75:4705-12.
46. Qin JZ, Chaturvedi V, Denning MF, Bacon P, Panella J, Choubey D et al. Regulation of apoptosis by P53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes. Oncogene 2002;21:2991-3002.
47. Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000;19:592-8.
48. Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000;14:3065-73.
49. Jackson S, Ghali L, Harwood C, Storey A. Reduced apoptotic levels in squamous but not basal cell carcinomas correlates with detection of cutaneous human papillomavirus. Br J Cancer 2002;87:319-23.
50. Zhang B, Spandau DF, Roman A. E5 protein of human papillomavirus type 16 protects human foreskin form UVB-irradiation-induced apoptosis. J Virol 2002;76:220-31.
51. Simbulan-Rosenthal CM, Velena A, Veldman T, Schlegel R, Rosenthal DS. HPV E6/7 immortalization sensitizes human keratinocytes to UVB by altering the pathway from caspase-8 to caspase-9-dependent apoptosis. J Biol Chem 2002;277:24709-16.
52. Ford JM, Baron EL, Hanawalt PC. Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res 1998;58:599-603.
53. Rey O, Lee S, Park NH. Impaired nucleotide excision repair in UV-irradiated human oral keratinocytes immortalized with type 16 human papillomavirus genome. Oncogene 1999;18:6997-7001.
54. El-Mahdy MA, Hamada FM, Wani MA, Zhu Q, Wani AA. P53-degradation by HPV-16 E6 preferentially affects the removal of cyclobutane pyrimidine dimers from non-transcribed strand and sensitizes mammary epithelial cells to UV-irradiation. Mutat Res 2000;459:135-45.
55. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C et al. A randomized, double-blind, vehicle-controlled study to assess 5 p.100 imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502.
56. Frazer IH, Thomas R, Zhou J, Leggatt GR, Dunn L, McMillan N et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 1999;168:131-42.